AEON Biopharma, Inc. (AEON): R&D Expense
$4.09M
Year ended 2025-12-31
$7.18M
Trailing 12 months to 2026-06-30
-51.0%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.09M | -71.1% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $14.18M | n/a | 2026-03-30, From 2024-01-01 |
| No annual figure between 2022-12-31 and 2024-12-31. | |||
| 2022-12-31 | $34.75M | n/a | 2024-03-29, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $4.09M | -71.1% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| CDT Equity Inc. (CDT) | 2025-12-31 | $5.05M | +49.6% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $4.16M | -9.7% |
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $6.27M | +122.9% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $2.62M | +8.5% |
| Enveric Biosciences, Inc. (ENVB) | 2025-12-31 | $2.78M | -2.1% |
Compare AEON, JUNS, CDT, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗